Value of a secretomic approach for distinguishing patients with COVID‐19 viral pneumonia among patients with respiratory distress admitted to intensive care unit

Abstract

AbstractIn intensive care units, COVID‐19 viral pneumonia patients (VPP) present symptoms similar to those of other patients with Nonviral infection (NV‐ICU). To better manage VPP, it is therefore interesting to better understand the molecular pathophysiology of viral pneumonia and to search for biomarkers that may clarify the diagnosis. The secretome being a set of proteins secreted by cells in response to stimuli represents an opportunity to discover new biomarkers. The objective of this study is to identify the secretomic signatures of VPP with those of NV‐ICU. Plasma samples and clinical data from NV‐ICU (n = 104), VPP (n = 30) or healthy donors (HD, n = 20) were collected at Nantes Hospital (France) upon admission. Samples were enriched for the low‐abundant proteins and analyzed using nontarget mass spectrometry. Specifically deregulated proteins (DEP) in VPP versus NV‐ICU were selected. Combinations of 2 to 4 DEPs were established. The differences in secretome profiles of the VPP and NV‐ICU groups were highlighted. Forty‐one DEPs were specifically identified in VPP compared to NV‐ICU. We describe five of the best combinations of 3 proteins (complement component C9, Ficolin‐3, Galectin‐3‐binding protein, Fibrinogen alpha, gamma and beta chain, Proteoglycan 4, Coagulation factor IX and Cdc42 effector protein 4) that show a characteristic receptor function curve with an area under the curve of 95.0%. This study identifies five combinations of candidate biomarkers in VPP compared to NV‐ICU that may help distinguish the underlying causal molecular alterations.